HPV18 E7 Inhibitors
HPV18 E7 inhibitors encompass a group of compounds that can either directly or indirectly hinder the function of the HPV18 E7 protein within cellular pathways. These inhibitors target specific biochemical and cellular processes that are exploited by HPV18 E7 to promote its oncogenic activities. For instance, compounds like retinoic acid, curcumin, and resveratrol indirectly inhibit HPV18 E7 by modulating the expression and stability of key proteins, such as Rb and p53, which are central to E7-mediated cell cycle progression and survival regulation. By doing so, these chemicals interfere with the intricate web of molecular interactions that E7 relies on for its activity.
Additionally, HPV18 E7 inhibitors like cisplatin and AZD8055 disrupt critical signaling pathways, such as the PI3K/Akt and mTORC1 pathways, which E7 hijacks to support its pro-survival and proliferative functions. Furthermore, JAK inhibitors, bortezomib, SB203580, and sorafenib indirectly hinder E7 by interfering with the JAK/STAT, proteasome, p38 MAPK, and RAF/MEK/ERK pathways, respectively, which are associated with E7-mediated immune evasion, inflammation, and cell proliferation. Collectively, the chemical class of HPV18 E7 inhibitors presents a spectrum of compounds with diverse mechanisms of action, all aimed at disrupting the cellular processes and pathways that enable HPV18 E7 to exert its oncogenic effects.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid can modulate the expression of Rb protein, which is targeted by HPV18 E7 for degradation. By upregulating Rb, retinoic acid indirectly inhibits HPV18 E7's ability to promote cell cycle progression. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin has been shown to downregulate NF-κB signaling pathway, which is involved in HPV18 E7 expression. Inhibition of this pathway by curcumin can indirectly reduce HPV18 E7 levels. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol can activate SIRT1, a deacetylase enzyme that targets HPV18 E7 for degradation by deacetylating it. This leads to the indirect inhibition of HPV18 E7 activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits the PI3K/Akt pathway, which is associated with HPV18 E7's pro-survival function. This indirect inhibition can result in reduced HPV18 E7-mediated cell survival. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin induces DNA damage, leading to the activation of p53. Elevated p53 levels can counteract the oncogenic effects of HPV18 E7, making it an indirect inhibitor of E7. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an mTOR inhibitor that can disrupt the mTORC1 pathway. HPV18 E7 is known to activate mTORC1, so AZD8055 indirectly inhibits E7-mediated cell proliferation. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil can inhibit DNA synthesis and repair processes, indirectly affecting the stability and function of HPV18 E7, which relies on these cellular processes for its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that can suppress the PI3K/Akt pathway. HPV18 E7 exploits this pathway for its anti-apoptotic effects, so wortmannin indirectly inhibits E7's function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the proteasome, preventing the degradation of p53. Elevated p53 levels can counteract HPV18 E7's oncogenic effects, making bortezomib an indirect inhibitor of E7. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can disrupt the p38 MAPK pathway, which is related to HPV18 E7's pro-inflammatory activity. This indirectly inhibits E7-mediated inflammation. | ||||||